blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2820424

EP2820424 - SOLUBLE MANF IN PANCREATIC BETA-CELL DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.10.2017
Database last updated on 23.04.2024
FormerThe patent has been granted
Status updated on  04.11.2016
FormerGrant of patent is intended
Status updated on  31.10.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
University of Massachusetts
333 South Street
Suite 400
Shrewsbury, Massachusetts 01545 / US
[2015/02]
Inventor(s)01 / URANO, Fumihiko
13 Rio Vista Drive
Saint Louis, Missouri 63124 / US
02 / KANEKURA, Kohsuke
9197 Wrenwood Lane
Brentwood, Missouri 63144 / US
 [2015/02]
Representative(s)Donald, Jenny Susan, et al
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
[N/P]
Former [2015/02]Donald, Jenny Susan, et al
Forresters
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
Application number, filing date13741203.723.01.2013
[2016/49]
WO2013US22768
Priority number, dateUS201261590021P24.01.2012         Original published format: US 201261590021 P
[2015/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013112602
Date:01.08.2013
Language:EN
[2013/31]
Type: A1 Application with search report 
No.:EP2820424
Date:07.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 01.08.2013 takes the place of the publication of the European patent application.
[2015/02]
Type: B1 Patent specification 
No.:EP2820424
Date:07.12.2016
Language:EN
[2016/49]
Search report(s)International search report - published on:KR01.08.2013
(Supplementary) European search report - dispatched on:EP22.09.2015
ClassificationIPC:G01N33/68, G01N33/50, A61K38/18, A61K31/473
[2015/43]
CPC:
G01N33/6893 (EP,CN,US); G01N33/6872 (US); A61K31/473 (EP,US);
A61K38/1709 (EP,US); A61K38/185 (EP,US); A61K38/28 (EP,US);
A61K45/06 (EP,US); A61P1/18 (EP); A61P3/10 (EP);
A61P43/00 (EP); C07K14/47 (US); C12N15/1136 (EP,US);
G01N33/5038 (US); G01N33/507 (US); C12N2310/14 (EP,US);
G01N2333/475 (US); G01N2500/10 (US); G01N2800/04 (EP,US);
G01N2800/042 (EP,CN,US); G01N2800/50 (US) (-)
C-Set:
A61K31/473, A61K2300/00 (US,EP);
A61K38/185, A61K2300/00 (EP,US);
A61K38/28, A61K2300/00 (US,EP)
Former IPC [2015/30]G01N33/68, G01N33/50, A61K38/18
Former IPC [2015/02]G01N33/68, G01N33/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/02]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:LÖSLICHER MANF IN PANKREAS-BETAZELLEN-ERKRANKUNGEN[2015/02]
English:SOLUBLE MANF IN PANCREATIC BETA-CELL DISORDERS[2015/02]
French:MANF SOLUBLE DANS LES TROUBLES DES CELLULES BÊTA PANCRÉATIQUES[2015/02]
Entry into regional phase22.08.2014National basic fee paid 
22.08.2014Search fee paid 
22.08.2014Designation fee(s) paid 
22.08.2014Examination fee paid 
Examination procedure22.08.2014Examination requested  [2015/02]
11.04.2016Amendment by applicant (claims and/or description)
14.06.2016Communication of intention to grant the patent
20.10.2016Fee for grant paid
20.10.2016Fee for publishing/printing paid
20.10.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.06.2016
Opposition(s)08.09.2017No opposition filed within time limit [2017/46]
Fees paidRenewal fee
27.01.2015Renewal fee patent year 03
27.01.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.01.2013
AL07.12.2016
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
MK07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
TR07.12.2016
IE23.01.2017
LU23.01.2017
MT23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
[2020/34]
Former [2020/15]HU23.01.2013
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
MK07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
TR07.12.2016
IE23.01.2017
LU23.01.2017
MT23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2019/51]HU23.01.2013
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
MK07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
IE23.01.2017
LU23.01.2017
MT23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2019/47]HU23.01.2013
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
IE23.01.2017
LU23.01.2017
MT23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2019/31]HU23.01.2013
AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
IE23.01.2017
LU23.01.2017
MT23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2018/43]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
IE23.01.2017
LU23.01.2017
MT23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2018/13]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
IE23.01.2017
LU23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2017/51]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
LU23.01.2017
CH31.01.2017
LI31.01.2017
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2017/42]AT07.12.2016
BE07.12.2016
CZ07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2017/38]AT07.12.2016
BE07.12.2016
CZ07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2017/37]AT07.12.2016
BE07.12.2016
CZ07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SK07.12.2016
SM07.12.2016
NO07.03.2017
GR08.03.2017
IS07.04.2017
Former [2017/36]BE07.12.2016
CZ07.12.2016
EE07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
LT07.12.2016
LV07.12.2016
NL07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SK07.12.2016
NO07.03.2017
GR08.03.2017
IS07.04.2017
Former [2017/34]CZ07.12.2016
ES07.12.2016
FI07.12.2016
HR07.12.2016
LT07.12.2016
LV07.12.2016
NL07.12.2016
RS07.12.2016
SE07.12.2016
BE31.01.2017
NO07.03.2017
GR08.03.2017
Former [2017/31]ES07.12.2016
FI07.12.2016
HR07.12.2016
LT07.12.2016
LV07.12.2016
NL07.12.2016
RS07.12.2016
SE07.12.2016
BE31.01.2017
NO07.03.2017
GR08.03.2017
Former [2017/28]ES07.12.2016
FI07.12.2016
HR07.12.2016
LT07.12.2016
LV07.12.2016
RS07.12.2016
SE07.12.2016
BE31.01.2017
NO07.03.2017
GR08.03.2017
Former [2017/12]LV07.12.2016
Documents cited:Search[X]WO2004010946  (DOMANI SCIENCES LLC [US]) [X] 1,5-9 * page 4, line 19 - page 5, line 15; claims 15-16 *;
 [X]US2008200453  (CINCOTTA ANTHONY H [US]) [X] 1,5-9 * paragraph [0066] - paragraph [0067]; claims 1,3,8 *;
 [X]WO2008150480  (VEROSCIENCE LLC [US]) [X] 1,5-9 * page 36, line 5 - page 37, line 9 *;
 [X]WO2010072383  (7ROCHE DIAGNOSTICS GMBH [DE], et al) [X] 10,12-14 * page 19, line 28 - page 19, line 32; claim 2 * * page 23, line 5 - line 8 * * page 22, line 26 - page 23, line 28 * * page 25, line 6 - line 10 * * examples 2,3; claim 11 *;
 [X]WO2011069051  (CALIPER LIFE SCIENCES INC [US], et al) [X] 1,5-9* page 11, line 16 - line 30; claims 12-13 *;
 [A]WO2011143788  (ZHEJIANG BETA PHARMA INC [CN], et al) [A] 1-14 * abstract *;
 [A]WO2011152658  (CELLTRION CHEMICAL RES INST [KR], et al) [A] 1-14 * abstract *;
 [X]WO2011156248  (VEROSCIENCE LLC [US], et al) [X] 1,5-9 * page 37, line 20 - page 38, line 25; claims 18,39-40 *;
 [E]WO2013034805  (ARUMAEE URMAS [FI], et al) [E] 1-14 * page 2, line 26 - page 3, line 3 * * page 12, line 23 - line 32 *;
 [T]  - MARIA LINDAHL ET AL, "MANF Is Indispensable for the Proliferation and Survival of Pancreatic [beta] Cells", CELL REPORTS, (20140401), vol. 7, no. 2, doi:10.1016/j.celrep.2014.03.023, ISSN 2211-1247, pages 366 - 375, XP055161920 [T] 1-14

DOI:   http://dx.doi.org/10.1016/j.celrep.2014.03.023
International search[A]US2002182198  (COMMISSIONG JOHN W [CA], et al);
 [A]US2009282495  (SAARMA MART [FI], et al);
 [A]US2011212055  (COMMISSIONG JOHN W [US]);
 [A]  - TADIMALLA ET AL., "Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an ischemia-inducible secreted endoplasmic reticulum (ER) stress response protein in the heart", CIRCULATION RESEARCH, (20081121), vol. 103, no. 11, pages 1249 - 1258, XP002591352

DOI:   http://dx.doi.org/10.1161/circresaha.108.180679
 [A]  - VOUTILAINEN ET AL., "'Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of parkinson's disease'", THE JOURNAL OF NEUROSCIENCE, (20090729), vol. 29, no. 30, pages 9651 - 9659, XP055160136

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.0833-09.2009
by applicantUS5223409
 US5403484
 US5571698
 US5716928
 US5858401
 US6007839
 US6063400
 US2004028670
 US2011123443
    - PIPELEERS ET AL., NOVARTIS FOUND SYMP., (2008), vol. 292, pages 19 - 24
    - OSLOWSKI ET AL., CURR. OPIN. ENDOCRINOL. DIABETES OBES., (2010), vol. 17, pages 107 - 112
    - OSLOWSKI ET AL., CURR. OPIN. CELL BIOL., (2011), vol. 23, pages 207 - 215
    - FONSECA ET AL., TRENDS ENDOCRINOL. METAB., (2011), vol. 22, pages 266 - 274
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 444 - 453
    - ALTSCHUL ET AL., NUCLEIC ACIDS RESEARCH, (1997), vol. 25, pages 3389 - 3402
    - SOLA ET AL., J. PHARM. SCI., (2009), vol. 98, pages 1123 - 1245
    - MINTO, J. PHARMACOL. EXP. THER., (1997), vol. 281, pages 93 - 102
    - ROHATAGI, J. CLIN. PHARMACOL., (1995), vol. 35, pages 1187 - 1193
    - TJWA, ANN. ALLERGY ASTHMA IMMUNOL., (1995), vol. 75, pages 107 - 111
    - RAO, J. BIOMATER SCI. POLYM. ED., (1995), vol. 7, pages 623 - 645
    - GAO, PHARM. RES., (1995), vol. 12, pages 857 - 863
    - EYLES, J. PHARM. PHARMACOL., (1997), vol. 49, pages 669 - 674
    - AL-MUHAMMED, J. MICROENCAPSUL., (1996), vol. 13, pages 293 - 306
    - CHONN, CURR. OPIN. BIOTECHNOL., (1995), vol. 6, pages 698 - 708
    - OSTRO, AM. J. HOSP. PHARM., (1989), vol. 46, pages 1576 - 1587
    - HIDALGO-ARAGONES, J. STEROID BIOCHEM. MOL. BIOL., (1996), vol. 58, pages 611 - 617
    - GRONING, PHARMAZIE, (1996), vol. 51, pages 337 - 341
    - FOTHERBY, CONTRACEPTION, (1996), vol. 54, pages 59 - 69
    - JOHNSON, J. PHARM. SCI., (1995), vol. 84, pages 1144 - 1146
    - ROHATAGI, PHARMAZIE, (1995), vol. 50, pages 610 - 613
    - BROPHY, EUR. J. CLIN. PHARMACOL., (1983), vol. 24, pages 103 - 108
    - OSTERGAARD ET AL., EMBO J., (2001), vol. 20, pages 5853 - 5862
    - MERKSAMER ET AL., CELL, (2008), vol. 135, pages 933 - 947
    - DOOLEY ET AL., J. BIOL. CHEM., (2004), vol. 279, pages 22284 - 22293
    - SRINIVASAN ET AL., INDIAN J. MED. RES., (2007), vol. 125, pages 451 - 472
    - REES ET AL., DIABETIC MED., (2005), vol. 22, pages 359 - 370
    - LAM, ANTICANCER DRUG DES., (1997), vol. 12, page 145
    - DEWITT ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1993), vol. 90, page 6909
    - ERB ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1994), vol. 91, page 11422
    - ZUCKERMANN ET AL., J. MED. CHEM., (1994), vol. 37, page 2678
    - CHO ET AL., SCIENCE, (1993), vol. 261, page 1303
    - CARRELL ET AL., ANGEW. CHEM. INT. ED. ENGL., (1994), vol. 33, page 2059
    - CARELL ET AL., ANGEW. CHEM. INT. ED. ENGL., (1994), vol. 33, page 2061
    - GALLOP ET AL., J. MED. CHEM., (1994), vol. 37, page 1233
    - HOUGHTEN, BIO/TECHNIQUES, (1992), vol. 13, pages 412 - 421
    - LAM, NATURE, (1991), vol. 354, pages 82 - 84
    - FODOR, NATURE, (1993), vol. 364, pages 555 - 556
    - CULL ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1992), vol. 89, pages 1865 - 1869
    - SCOTT; SMITH, SCIENCE, (1990), vol. 249, pages 386 - 390
    - DEVLIN, SCIENCE, (1990), vol. 249, pages 404 - 406
    - CWIRLA ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1990), vol. 87, pages 6378 - 6382
    - FELICI, J. MOL. BIOL., (1991), vol. 222, pages 301 - 310
    - RIGGS ET AL., DIABETOLOGIA, (2005), vol. 48, pages 2313 - 2321
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.